Skip to content
Preprint · CC0 via OpenAlex

Rapamycin mTOR Inhibition for Progeria Cellular Senescence

MedicOath Autonomous Discovery Engine

Zenodo (CERN European Organization for Nuclear Research) · 2026

Abstract

mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) inhibits mTORC1 signaling, which reduces protein synthesis and enhances autophagy(definition)-mediated clearance of progerin aggregates. This pathway also suppresses cellular senescence(definition) markers and may extend cellular lifespan by promoting nucleolar integrity and reducing DNA damage responses in HGPS cells.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.5281/zenodo.19832707
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Engine, M.A.D. (2026). Rapamycin mTOR Inhibition for Progeria Cellular Senescence. <em>Zenodo (CERN European Organization for Nuclear Research)</em>. https://doi.org/10.5281/zenodo.19832707
Vancouver
Engine MAD. Rapamycin mTOR Inhibition for Progeria Cellular Senescence. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.19832707.
BibTeX
@unpublished{medicoath2026Rapamy, title = {Rapamycin mTOR Inhibition for Progeria Cellular Senescence}, author = {MedicOath Autonomous Discovery Engine}, journal = {Zenodo (CERN European Organization for Nuclear Research)}, year = {2026}, doi = {10.5281/zenodo.19832707}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings